 CAMBRIDGE, Mass.--BUSINESS WIRE--Axcella Nasdaq:AXLA, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator EMM compositions, today announced the appointment of Alison D. Schecter, M.D., as the companys President of Research and Development. In this role, Dr. Schecter will oversee all of the companys research, product candidate design, clinical and regulatory efforts. Additionally, Manu Chakrava 